Nahid A. Qushmaq: Advancing Anticoagulation Through Factor XI/XIa Inhibition
Nahid A. Qushmaq, General Supervisor Assistant for Medical Support Services, Consultant Adult Hematology of Thrombosis and Hemostasis, Head Of Research and Development Department at King Abdullah Medical Complex – Jeddah, shared a post on LinkedIn:
“One of the most valuable sessions I attended at ISTH 2026 was ‘Emerging Therapies in Thrombosis: Factor XI/XIa Inhibitors’, delivered by Dr. Jeffrey Weitz.
The session provided an excellent overview of the evolving role of FXI/FXIa inhibition in thrombosis prevention and highlighted the exciting potential of these novel agents to reduce thrombotic events while minimizing bleeding risk, making it one of the most promising next-generation anticoagulant strategies.
An insightful and thought-provoking session that reinforces how rapidly the field of thrombosis is advancing.”
Stay updates with Hemostasis Today.
-
Sep 19, 2026, 18:03Manisha Madkaikar: Clinical, Hematological, and Molecular Features of Sickle β-Thalassemia
-
Sep 19, 2026, 17:24Jan Shawqi Goran: Understanding Beta Thalassemia Before Marriage Testing
-
Sep 19, 2026, 14:17Abdul Mannan: What Exactly Is a Platelet?
-
Sep 19, 2026, 13:39Keisuke Goda: Decoding Platelet Phenotypes in COVID-19 With Optofluidic Imaging
-
Sep 19, 2026, 13:30Targeted Thrombolysis Beyond tPA
-
Sep 19, 2026, 13:21Paul Armstrong: From Summer Studentship to Young Researcher
-
Sep 19, 2026, 13:06Rabiya Masood: Breaking the Cycle of Thalassemia Through Screening
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community